Skip to main content

Table 3 Performance of diagnostic indices

From: Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers

Study Index Designed sensitivity cutoff Sensitivity (CI) Specificity (CI) Accuracy (CI) AUC (CI) TP TN FP FN
Performance of diagnostic indices developed on PC vs. HS
PC vs. HS I 0.85 −9.13 84.85 (78.45–89.95) 100.00 (90.00–100.00) 87.50 (82.10–91.74) 1.00 (1.00–1.00) 140 35 0 25
A-AC vs. HS I   −9.13 74.58 (61.56–85.02) 100.00 (90.00–100.00) 84.04 (75.05–90.78) 0.99 (0.96–1.00) 44 35 0 15
DC vs. HS I   −9.13 100.00 (54.07–100.00) 100.00 (90.00–100.00) 100.00 (91.40–100.00) 1.00 (1.00–1.00) 6 35 0 0
CBD vs. HS I   −9.13 66.67 (43.03–85.41) 100.00 (90.00–100.00) 87.50 (75.93–94.82) 1.00 (0.99–1.00) 14 35 0 7
A-AC, DC, CBD vs. HS I   −9.13 74.42 (63.87–83.22) 100.00 (90.00–100.00) 81.82 (73.78–88.24) 0.99 (0.97–1.00) 64 35 0 22
GC vs. HS I   −9.13 100.00 (83.16–100.00) 100.00 (90.00–100.00) 100.00 (93.51–100.00) 1.00 (1.00–1.00) 20 35 0 0
PC vs. HS II 0.85 16.68 84.85 (78.45–89.95) 100.00 (90.00–100.00) 87.50 (82.10–91.74) 1.00 (1.00–1.00) 140 35 0 25
A-AC vs. HS II   16.68 67.80 (54.36–79.38) 100.00 (90.00–100.00) 79.79 (70.25–87.37) 0.94 (0.89–0.98) 40 35 0 19
DC vs. HS II   16.68 83.33 (35.88–99.58) 100.00 (90.00–100.00) 97.56 (87.14–99.94) 1.00 (1.00–1.00) 5 35 0 1
CBD vs. HS II   16.68 80.95 (58.09–94.55) 100.00 (90.00–100.00) 92.86 (82.71–98.02) 0.97 (0.90–1.00) 17 35 0 4
A-AC, DC, CBD vs. HS II   16.68 72.09 (61.38–81.23) 100.00 (90.00–100.00) 80.17 (71.94–86.86) 0.95 (0.91–0.99) 62 35 0 24
GC vs. HS II   16.68 95.00 (75.13–99.87) 100.00 (90.00–100.00) 98.18 (90.28–99.95) 0.96 (0.87–1.00) 19 35 0 1
PC vs. HS III 0.85 149.10 84.85 (78.45–89.95) 100.00 (90.00–100.00) 87.50 (82.10–91.74) 1.00 (1.00–1.00) 140 35 0 25
A-AC vs. HS III   149.10 72.88 (59.73–83.64) 100.00 (90.00–100.00) 82.98 (73.84–89.95) 0.98 (0.95–1.00) 43 35 0 16
DC vs. HS III   149.10 66.67 (22.28–95.67) 100.00 (90.00–100.00) 95.12 (83.47–99.40) 1.00 (1.00–1.00) 4 35 0 2
CBD vs. HS III   149.10 71.43 (47.82–88.72) 100.00 (90.00–100.00) 89.29 (78.12–95.97) 1.00 (0.99–1.00) 15 35 0 6
A-AC, DC, CBD vs. HS III   149.10 72.09 (61.38–81.23) 100.00 (90.00–100.00) 80.17 (71.94–86.86) 0.99 (0.97–1.00) 62 35 0 24
GC vs. HS III   149.10 100.00 (83.16–100.00) 100.00 (90.00–100.00) 100.00 (93.51–100.00) 1.00 (1.00–1.00) 20 35 0 0
Performance of diagnostic indices developed on PC vs. HS + CP
PC vs. HS + CP IV 0.85 −9.13 84.85 (78.45–89.95) 75.68 (64.31–84.90) 82.01 (76.54–86.66) 0.89 (0.84–0.94) 140 56 18 25
A-AC vs. HS + CP IV   −9.13 74.58 (61.56–85.02) 75.68 (64.31–84.90) 75.19 (66.96–82.26) 0.83 (0.76–0.90) 44 56 18 15
DC vs. HS + CP IV   −9.13 100.00 (54.07–100.00) 75.68 (64.31–84.90) 77.50 (66.79–86.09) 0.85 (0.76–0.93) 6 56 18 0
4 vs. HS + CP IV   −9.13 66.67 (43.03–85.41) 75.68 (64.31–84.90) 73.68 (63.65–82.19) 0.80 (0.71–0.88) 14 56 18 7
A-AC, DC, CBD vs. HS + CP IV   −9.13 74.42 (63.87–83.22) 75.68 (64.31–84.90) 75.00 (67.55–81.50) 0.83 (0.76–0.89) 64 56 18 22
CG vs. HS + CP IV   −9.13 100.00 (83.16–100.00) 75.68 (64.31–84.90) 80.85 (71.44–88.24) 0.97 (0.93–1.00) 20 56 18 0
PC vs. HS + CP V 0.85 1.38 84.85 (78.45–89.95) 91.89 (83.18–96.97) 87.03 (82.10–91.01) 0.96 (0.94–0.98) 140 68 6 25
A-AC vs. HS + CP V   1.38 77.97 (65.27–87.71) 91.89 (83.18–96.97) 85.71 (78.59–91.17) 0.93 (0.87–0.97) 46 68 6 13
DC vs. HS + CP V   1.38 100.00 (54.07–100.00) 91.89 (83.18–96.97) 92.50 (84.39–97.20) 1.00 (0.98–1.00) 6 68 6 0
CBD vs. HS + CP V   1.38 85.71 (63.66–96.95) 91.89 (83.18–96.97) 90.53 (82.78–95.58) 0.94 (0.89–0.98) 18 68 6 3
A-AC, DC, CBD vs. HS + CP V   1.38 81.40 (71.55–88.98) 91.89 (83.18–96.97) 86.25 (79.93–91.18) 0.94 (0.89–0.97) 70 68 6 16
GC vs. HS + CP V   1.38 95.00 (75.13–99.87) 91.89 (83.18–96.97) 92.55 (85.26–96.95) 0.99 (0.96–1.00) 19 68 6 1
PC vs. HS + CP VI 0.85 1.46 84.85 (78.45–89.95) 93.24 (84.93–97.77) 87.45 (82.57–91.37) 0.97 (0.95–0.99) 140 69 5 25
A-AC vs. HS + CP VI   1.46 72.88 (59.73–83.64) 93.24 (84.93–97.77) 84.21 (76.88–89.95) 0.92 (0.87–0.96) 43 69 5 16
DC vs. HS + CP VI   1.46 100.00 (54.07–100.00) 93.24 (84.93–97.77) 93.75 (86.01–97.94) 0.99 (0.97–1.00) 6 69 5 0
CBD vs. HS + CP VI   1.46 76.19 (52.83–91.78) 93.24 (84.93–97.77) 89.47 (81.49–94.84) 0.93 (0.87–0.98) 16 69 5 5
A-AC, DC, CBD vs. HS + CP VI   1.46 75.58 (65.13–84.20) 93.24 (84.93–97.77) 83.75 (77.10–89.10) 0.93 (0.89–0.96) 65 69 5 21
GC vs. HS + CP VI   1.46 75.00 (50.90–91.34) 93.24 (84.93–97.77) 89.36 (81.30–94.78) 0.91 (0.80–0.98) 15 69 5 5
  1. AUC Area under Curve, TP True positive, TN True negative, FP False positive, FN False negative, PC Pancreatic Cancer, A-AC Ampullary Adenocarcinoma, DC Duodenal Cancer, CBD Common bile duct cancer, GC Gastric cancer, HS Healthy subjects